Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Cadrock Raises $5 Million from China Investor for Antibiotic CAD Treatment

publication date: Sep 10, 2018

Cadrock Pty Ltd, of Australia has raised $5 million in seed financing from an unnamed China investor to support clinical trials of an investigational triple-antibiotic as a treatment for coronary artery disease (CAD). The theory that CAD is caused by bacterial infection has not been proven, though a British study showed a 36% reduction in Major Cardiac Events following a course of antibiotics. The therapy was developed by Thomas Borody, MD, PhD, who previously developed a triple antibiotic treatment for peptic ulcers. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China